Verona Pharma plc Verona Pharma To Present At Lsx World Congress 2020

 
TIDMVRP 
 
   LONDON, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) 
(Nasdaq: VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical 
company focused on respiratory diseases, announces that Piers Morgan, 
CFO of Verona Pharma, will present a corporate overview and host 
one-on-one meetings at the LSX World Congress taking place in London on 
February 4-5, 2020. 
 
   Presentation details are as follows: 
 
 
 
 
Date:                              Tuesday, February 4, 2020 
Time:                              1:45 PM GMT (8:45 AM EST) 
Track:                             InvEUR$table Biotech 
Location:                          London, UK 
 
 
   For six years, the 
https://www.globenewswire.com/Tracker?data=Lg0vLSuFSThqFs6JMqhj6-EiEhPx8cBY1WSt40UYr7O-962LVBo4E67r0lLmKitQcasu1ZN-ydhu35Z6ij5z28FBhvquexdZ0F1HimrERlUnjLy__4Lwg2VLpIpIkbMe 
LSX World Congress has been bringing together executives in healthcare 
and life science strategy, investment, partnering and deal making. In 
2020, over 1000 executives will come to London including the biotech 
industry's C-suite, investors, pharma and healthtech teams, R&D leaders 
and KOLs. 
 
   About Verona Pharma 
 
   Verona Pharma is a clinical-stage biopharmaceutical company focused on 
developing and commercializing innovative therapies for the treatment of 
respiratory diseases with significant unmet medical needs. Verona 
Pharma's product candidate, ensifentrine, has the potential to be the 
first therapy for the treatment of respiratory diseases that combines 
bronchodilator and anti-inflammatory activities in one compound. Verona 
Pharma is currently in Phase 2 development with three formulations of 
ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, 
and pressurized metered-dose inhaler. Ensifentrine also has potential 
applications in cystic fibrosis, asthma and other respiratory diseases. 
For more information, please visit 
https://www.globenewswire.com/Tracker?data=ikNtg_c1ALhVc5uhzEHzv5LMC9INh_SiLukn75fQh520nQhX5pFPAeY_AW1RwCW-2LB5kKx5sC-wR1K1v86fL85e9_o43seOKyIFSoaHC1w= 
www.veronapharma.com. 
 
   Forward-Looking Statements 
 
   This press release contains forward-looking statements. All statements 
contained in this press release that do not relate to matters of 
historical fact should be considered forward-looking statements, 
including, but not limited to, the development of ensifentrine, the 
progress and timing of clinical trials and data, estimates of medical 
costs for COPD, ensifentrine as a first-in-class phosphodiesterase 3 and 
4 inhibitor, and plans to develop ensifentrine for the treatment of 
cystic fibrosis and asthma. 
 
   These forward-looking statements are based on management's current 
expectations. These statements are neither promises nor guarantees, but 
involve known and unknown risks, uncertainties and other important 
factors that may cause our actual results, performance or achievements 
to be materially different from our expectations expressed or implied by 
the forward-looking statements, including, but not limited to, the 
following: our limited operating history; our need for additional 
funding to complete development and commercialization of ensifentrine, 
which may not be available and which may force us to delay, reduce or 
eliminate our development or commercialization efforts; the reliance of 
our business on the success of ensifentrine, our only product candidate 
under development; economic, political, regulatory and other risks 
involved with international operations; the lengthy and expensive 
process of clinical drug development, which has an uncertain outcome; 
serious adverse, undesirable or unacceptable side effects associated 
with ensifentrine, which could adversely affect our ability to develop 
or commercialize ensifentrine; potential delays in enrolling patients, 
which could adversely affect our research and development efforts and 
the completion of our Phase 2b trial; we may not be successful in 
developing ensifentrine for multiple indications; our ability to obtain 
approval for and commercialize ensifentrine in multiple major 
pharmaceutical markets; misconduct or other improper activities by our 
employees, consultants, principal investigators, and third-party service 
providers; material differences between our "top-line" data and final 
data; our reliance on third parties, including clinical investigators, 
manufacturers and suppliers, and the risks related to these parties' 
ability to successfully develop and commercialize ensifentrine; and 
lawsuits related to patents covering ensifentrine and the potential for 
our patents to be found invalid or unenforceable. These and other 
important factors under the caption "Risk Factors" in our Annual Report 
on Form 20-F filed with the Securities and Exchange Commission ("SEC") 
on March 19, 2019, and our other reports filed with the SEC, could cause 
actual results to differ materially from those indicated by the 
forward-looking statements made in this press release. Any such 
forward-looking statements represent management's estimates as of the 
date of this press release. While we may elect to update such 
forward-looking statements at some point in the future, we disclaim any 
obligation to do so, even if subsequent events cause our views to 
change. These forward-looking statements should not be relied upon as 
representing our views as of any date subsequent to the date of this 
press release. 
 
   For further information, please contact: 
 
 
 
 
Verona Pharma plc                                        Tel: +44 (0)20 3283 4200 
Jan-Anders Karlsson, Chief Executive Officer             info@veronapharma.com 
David Moskowitz, VP Capital Markets Strategy & Investor 
 Relations (Investor enquiries) 
 Victoria Stewart, Director of Communications (Media 
 Enquiries) 
 
Optimum Strategic Communications                         Tel: +44 (0)20 950 9144 
 (European Media and Investor Enquiries)                  verona@optimumcomms.com 
Mary Clark / Eva Haas / Hollie Vile 
 
Argot Partners                                           Tel: +1 212-600-1902 
 (US Investor Enquiries)                                  verona@argotpartners.com 
Stephanie Marks / Kimberly Minarovich / Michael Barron
(END) Dow Jones Newswires
January 28, 2020 02:00 ET (07:00 GMT)
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Jun 2024 to Jul 2024